XML 39 R31.htm IDEA: XBRL DOCUMENT v3.26.1
Collaboration Agreement with GSK - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 06, 2026
Aug. 17, 2021
USD ($)
Jul. 01, 2021
USD ($)
May 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development expense           $ 19,460 $ 27,611 $ 37,317 $ 61,252  
Subsequent Event                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Agreement termination date Jan. 02, 2027                  
GlaxoSmithKline plc                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Effective date of agreement   Aug. 17, 2021                
Upfront payments     $ 700,000         $ 700,000    
Milestone payment received   $ 500,000     $ 200,000          
Percentage Of Development Cost               0.60    
Collaboration revenue           3,300 7,900 $ 4,400 11,500  
Deferred revenue           162,900   162,900   $ 171,200
Research and development expense           300 $ 6,100 1,500 $ 10,400  
Transaction price           564,000   564,000    
Contract with customer, refund liability           0   0   $ 11,400
Maximum funding       $ 140,500            
GlaxoSmithKline plc | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Additional milestone payments related to initiation of certain clinical studies and regulatory approval           $ 1,500,000   $ 1,500,000    
Alector                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Percentage Of Development Cost               0.40